Clinical Trials
9 trialsNCT07467629 2026-05-19
QLS5212 for Participants With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07584954 2026-05-13
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
ImmunoUrchin
Phase 1 Recruiting
NCT07492173 2026-03-25
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
Shandong New Time Pharmaceutical Co., LTD
Phase NA Completed
NCT07441174 2026-02-27
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07146672 2025-08-28
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Shanghai Cell Therapy Group Co.,Ltd
Phase 1/2 Recruiting
NCT00085878 2008-10-16
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00119171 2008-10-16
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00136513 2008-10-16
SB-743921 In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00169520 2008-10-16
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed